Haoyuan Medicine(688131) has invested in the establishment of Guangzhou Shengquan Baijie Venture Capital Partnership (Limited Partnership), holding a 13.33% stake.

2026-03-31 13:11:31

Abstract generation in progress

Securities Star News. According to data compiled from the Tianyancha app, recently, Guangzhou Shengquan Baijie Venture Capital Fund Partnership Enterprise (Limited Partnership) was established. The legal representative is Xi’an Wojie Private Fund Management Co., Ltd. The registered capital is 150 million yuan. Its business scope includes: venture capital (limited to investing in non-listed enterprises); activities such as equity investment, investment management, and asset management using private funds (only after completing filing and registration with the China Securities Investment Fund Association may business activities be carried out). Equity penetration data shown in the Tianyancha app indicates that the company is jointly held by Haoyuan Pharmaceutical, Sinocell Biotech Co., Ltd., Juzhi Leading (Shanghai) Biotechnology Co., Ltd., and others.

Data source: Tianyancha app

The above content has been compiled by Securities Star based on publicly available information and generated by an AI algorithm (website information filing No. 310104345710301240019). It does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.